Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

561. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. (Abstract)

Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. Since the last comprehensive review of anticoagulation in acute myocardial infarction four additional randomized control trials have been reported. The overwhelming majority of all trials favored anticoagulation. Rates of thromboembolism were higher in the control, and hemorrhagic complications in the anticoagulated group. Pooling of all randomized control trials gives mean case fatality rates (...) of 19.6% for the control and 15.4% for the anticoagulated group, a relative reduction of 21% (P less than 0.05 or less than 0.001, depending on the analytic method). Five of six randomized control trials reported "no effect" because the difference favoring anticoagulation was not statistically significant. However, sample sizes in these "negative" papers were too small to protect against missing a 21% reduction in true case fatality rate due to anticoagulation (beta greater than 0.10). All patients

1977 NEJM Controlled trial quality: uncertain

562. Anticoagulants in acute myocardial infarction. Results of a cooperative clinical trial. (Abstract)

Anticoagulants in acute myocardial infarction. Results of a cooperative clinical trial. 4578167 1973 09 21 2016 10 17 0098-7484 225 7 1973 Aug 13 JAMA JAMA Anticoagulants in acute myocardial infarction. Results of a cooperative clinical trial. 724-9 eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Anticoagulants 0 Placebos 5Q7ZVV76EI Warfarin 9005-49-6 Heparin 9NEZ333N27 Sodium AIM IM Acute Disease Adult Aged Anticoagulants adverse effects

1973 JAMA Controlled trial quality: uncertain

563. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. (Abstract)

Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. 4117261 1973 01 05 2016 10 17 0098-7484 222 5 1972 Oct 30 JAMA JAMA Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. 541-8 Drapkin A A Merskey C C eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Anticoagulants 0 (...) Placebos 5M7Y6274ZE Phenindione 5Q7ZVV76EI Warfarin 7QID3E7BG7 Dicumarol 9005-49-6 Heparin AIM IM Age Factors Aged Anticoagulants adverse effects therapeutic use Cerebrovascular Disorders mortality Clinical Trials as Topic Diabetes Complications Dicumarol therapeutic use Electrocardiography Female Heart Failure complications Hemorrhage chemically induced Heparin therapeutic use Humans Hypertension complications Male Middle Aged Myocardial Infarction complications drug therapy mortality Phenindione

1973 JAMA Controlled trial quality: uncertain

564. Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study. (Abstract)

Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study. 4885975 1969 04 16 2016 10 17 0098-7484 207 12 1969 Mar 24 JAMA JAMA Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study. 2263-7 Ebert R V RV eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Anticoagulants 97C5T2UQ7J Cholesterol AIM IM Anticoagulants

1969 JAMA Controlled trial quality: uncertain